The impact of body mass index on disease progression in ankylosing spondylitis by Zepa, Julija et al.
INTRODUCTION
Ankylosing spondylitis (AS) is a potentially disabling form
of systemic chronic inflammatory arthritis with a prevalence
from 0.02% in Sub-Saharan Africa to 0.35% in Northern
Arctic communities (Stolwijk et al., 2016). For example,
based on the nationwide, population-based study performed
in 2009, the prevalence of clinically diagnosed AS in Swe-
den was 0.18% (Exarchou et al., 2015). This disease usually
affects young male and female patients in their most pro-
ductive years (Rudwaleit et al., 2009). The main features of
AS are spinal inflammation and structural damage. How-
ever, many patients have concomitant extraspinal manifes-
tations classified as peripheral disease, such as arthritis, en-
thesitis and dactylitis, and/or extraarticular manifestations,
such as uveitis, psoriasis and inflammatory bowel disease
(IBD). Previous studies dated from 2004 till 2016 reported
18–58% prevalence of arthritis, 34–74% prevalence of en-
thesitis and 6–8% prevalence of dactylitis (reported at any
time during the disease course). The reported prevalence of
uveitis occurring at some point in time during the course of
AS varied from 22–37%, and the prevalence of IBD was es-
timated at 4–16% and the prevalence of psoriasis at 4–9%
(de Winter et al., 2016). Therefore, the course of the disease
can be very different, including low disease activity without
extraspinal manifestations and AS with late life-threatening
complications. How can we favourably modify the course
of the disease? There are many extraspinal modifiable fac-
tors usually analysed in different studies evaluating their in-
fluence on the course of chronic inflammatory arthritis, for
example, body mass index (BMI), smoking, D vitamin etc.
According to the BMI trend analysis to date, global obesity
numbers have increased dramatically, from 105 million
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Obesity can be a factor that affects the course of chronic systemic inflammatory arthritis. The ob-
jective of this study was to characterise patients with ankylosing spondylitis (AS) according to an
evaluation of their body mass index (BMI) and by exploring the link between the overweightness
and obesity with routinely measured disease-specific variables, including disease activity (Bath
Ankylosing Spondylitis Disease Activity Index BASDAI; Ankylosing Spondylitis Disease Activity
Score, using CRP, ASDAScrp), spinal mobility (Bath Ankylosing Spondylitis Metrology Index,
BASMI), functional capacity (BASFI), extraspinal manifestations like fatigue, uveitis, and periph-
eral arthritis present during the course of the disease. A total of 107 patients were included in the
cross-sectional study fulfilling the modified New York criteria for AS. Patients were divided into
three groups: with the evaluation of BMI  24.9, 25.0–29.9 (overweight) and  30.0 (obesity). The
mean BMI was 25.13 (SD 4.07). 33% of patients were overweight and 15% were obese. The
mean values of age, duration of AS, ASDAScrp, BASDAI, Bath Ankylosing Spondylitis Functional
Index (BASFI), BASMI, pain in spine, and fatigue in the group with BMI  24.9 were lower than in
the other groups (p < 0.05). There was no difference between groups in age of AS onset, uveitis
and peripheral arthritis. AS patients who were overweight or obese had a higher level of the dis-
ease activity, pain, fatigue, functional disability and spinal mobility impairment with worse values
in the case of obesity.
Key words: ankylosing spondylitis, body mass index, disease activity, functional disability,
obesity, overweight.
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adults in 1975 to 641 million in 2014. However, these sta-
tistics do not always include the population that is over-
weight. When the incidence of being overweight was in-
cluded within obesity statistics, rates of excess weight have
been shown to be dramatically greater. Indeed, the WHO re-
ported that, as a group, the obese and overweight adult
population is now approaching 40% of the world’s popula-
tion, with rates in the US now at ~66% (Maffetone et al.,
2017). The excess of adipose tissue in overweight and obese
individuals (routinely expressed by BMI) may have immu-
nodulating properties affecting the course of the disease
(Gremese et al., 2014). An increase in adipose tissue, which
is considered a dynamic endocrine organ, is associated with
increased production of several proinflammatory cytokines
(Vargas et al., 2016). To date no longitudinal study or
case-control study has investigated the effect of BMI on the
risk of AS development. However, analysis of some AS
clinical trial data, particularly AS population characteristics,
showed that BMI in AS patients is significantly higher in
comparison to the healthy population (Zhang and Ding,
2016).
Taking into account the increasing number of obese pa-
tients, worldwide investigation of the consequence of ex-
cess fat and of fat mass on the course of AS is relevant. The
role of fat tissue has not been widely investigated in AS, al-
though some trial data is available evaluating the influence
of BMI to the response to TNF inhibitors such as inflixi-
mab (Ottaviani et al., 2012) and adalimumab (Rosas et al.,
2016). The data from these studies suggest that overweight-
ness and obesity are associated with a lower rate of success
in achieving response status in AS patients. These argu-
ments prompted us to conduct a study evaluating the role of
BMI in the course of the AS, combined with routinely used
measurements.
The objective of this study was to characterise patients with
AS according to an evaluation of their BMI, exploring the
link between the overweightness and obesity with routinely
measured disease-specific variables, including disease ac-
tivity, spinal mobility, functional capacity, extraspinal
manifestations of the disease as fatigue, uveitis and periph-
eral arthritis present during the course of the disease.
MATERIALS AND METHODS
Patients. One hundred and seven patients were included in
the cross-sectional study fulfilling the modified New York
criteria for AS (van der Linden et al., 1984). The data pre-
sented here focus on patients with adult onset predomi-
nantly axial disease who were included in the study between
October 2011 and February 2016 in the Centre of Rheuma-
tology of Pauls Stradiòð Clinical University Hospital (inpa-
tient and outpatient department). The inclusion criteria were
an age > 18 years during the onset of the symptoms and ful-
filling the modified New York criteria for AS. The exclu-
sion criteria were other chronic or autoimmune inflamma-
tory arthritis (for example, rheumatoid arthritis), depression
or other psychiatric diseases diagnosed and/or treated by
psychiatrists, moderate or severe cardiac, pulmonary, renal
and/or hepatic insufficiency, acute or chronic infection,
CNS disorders recorded in medical reports, drug and/or al-
cohol abuse. Ethical approval was obtained for this study
from the local ethics committee at Pauls Stradiòð Clinical
University Hospital. Written informed consent was obtained
from all the patients in accordance with the principles of the
Declaration of Helsinki.
Patients were classified according to their BMI into three
groups: normal weight  24.9 kg/m2, overweight —
25.0–29.9 kg/m2, obesity was considered with BMI  30
kg/m2 (Anonymous, 2016). C-reactive protein (CRP) levels
were collected, and elevated CRP was considered if  5
mg/L. Disease activity was measured by the Bath Ankylos-
ing Spondylitis Disease Activity Index (BASDAI) (Garrett
et al., 1994) and by the Ankylosing Spondylitis Disease Ac-
tivity Score (ASDAS) (using CRP) (Machado et al., 2011).
BASDAI consists of 6 patient-reported outcomes, and has
an overall score from 0 to 10; evaluation 4 represents inac-
tive disease. ASDAS was calculated using the specific for-
mula, including evaluation of back pain (the second item of
BASDAI), duration of morning stiffness (the sixth item of
BASDAI), patient global, peripheral pain/swelling (the third
item of BASDAI) and CRP.
The following variables were chosen for overall characteris-
tics: age, duration of the disease, age of AS onset, duration
of morning stiffness (the sixth item of BASDAI; in min-
utes), functional (BASFI; 0–10) (Calin et al., 1995), metro-
logical (BASMI 3-point answer scale) (Jenkinson et al.,
1994) indices, evaluation of enthesitis (the fourth item of
BASDAI; 0–10), and uveitis and peripheral arthritis ever
during the course of the disease documented in medical re-
ports. Pain of the spine due to AS in the last week on aver-
age was evaluated using a NRS 0–10 (0–10: 0 — none;
10 — very severe) as well as patients’ global well-being
(0–10: 0 — no effect of the disease; 10 — very severe im-
pact). Fatigue was evaluated using the first item from
BASDAI questionnaire: “How would you describe the over-
all level of fatigue/tiredness you have?” The answer was re-
corded using a 0–10 numerical rating scale (NRS) (0 —
none and 10 — very severe).
Statistical analysis. Statistical analyses were performed us-
ing SPSS v.17.0. Results from categorical and dichotomous
variables were expressed as frequencies and continuous
variables as means and SDs. 2 tests were performed for the
comparison of categorical data, and the Kruskal-Wallis test
for the comparison of continuous variables, as appropriate.
P values less than 0.05 were considered significant.
RESULTS
The mean BMI was 25.13 (SD 4.07). In the study popula-
tion of 106 AS patients, 33% were overweight and 15%
were obese (one of the 107 AS patients lacked data for BMI
calculation).
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Demographic and clinical data of the 107 (85% males)
evaluated AS patients as well as data from the subgroups
enrolled in the study are summarised in Table 1.
The mean values of age, disease duration, CRP, ASDAScrp,
BASDAI, BASFI, BASMI in group 1 (BMI  24.9) were
lower than the parameters in the groups of patients who
were overweight (group 2) and obese (group 3). The evalua-
tion of fatigue and pain in spine was worse in groups 2 and
3. These differences were statistically significant between
the groups. There was no statistically significant difference
between the groups on age of AS onset, global well-being,
enthesitis evaluation and duration of morning stiffness.
55.1% of all patients had peripheral arthritis throughout the
course of the disease. 35.5% of all patients had uveitis re-
ported at any time during the course of the disease. There
was no statistically significant difference between the
groups in presence of peripheral arthritis (p = 0.769) or
uveitis (p = 0.614) during the course of the disease (Table
2).
DISCUSSION
The study confirmed the significant prevalence of over-
weightness and obesity in patients with AS. Similar results
were obtained, for example, from the Groningen Leewarden
Axial SpA cohort analysis — of 461 patients with axial
SpA, 37% were overweight and 22% were obese (Maas et
al., 2016).
How can we characterise the AS patient who is overweight
or obese? Based on our study, the typical patient is 42 years
old and has suffered from disease manifestation for 15 years
with high disease activity (supported also by elevated CRP
level in blood), a high level of spine pain, significantly ex-
pressed functional disability and restrictions on spinal mo-
bility accompanied by a marked expression of fatigue. Fur-
thermore, AS patients with obesity have higher disease
activity (ASDAScrp (p = 0.0060), BASDAI (p = 0.0088)),
functional (p = 0.0002) and spinal mobility (p = 0.0010) im-
pairment levels, fatigue (p = 0.0007) and pain in spine (p =
0.0119) evaluation scores than AS patients who are over-
weight.
Are there any differences in comparison with an AS patient
with normal BMI? The answer is “yes”. Based on the ob-
tained data, in cases with normal BMI, patients had the fol-
lowing profile: 36 years old patients suffering from disease
expression for 10 years with lower (on average moderate)
disease activity with some functional disability and restric-
tions on spinal mobility accompanied by a lower evaluation
T a b l e 1













Age (years) 38.83 (9.69) 36.2 (10.2) 41.06 (8.49) 43.5 (7.87) 0.0106
Disease duration (years) 12.63 (8.02) 10.38 (7.79) 13.86 (7.67) 18.31 (6.23) 0.0008
Age of the onset of AS (years) 26.12 (7.02) 25.81 (6.79) 27.31 (7.61) 24.38 (6.58) 0.3269
BASDAI (0–10) 4.44 (2.25) 3.77 (2.03) 4.96 (2.43) 5.46 (1.97) 0.0088
ASDAScrp 2.79 (1.32) 2.39 (1.32) 3.12 (1.29) 3.39 (0.99) 0.0060
CRP (mg/L) 12.8 (18.08) 11.72 (21.61) 13.86 (13.93) 14.19 (13.36) 0.0104
BASFI (0–10) 3.41 (2.68) 2.53 (2.43) 3.91 (2.56) 5.49 (2.41) 0.0002
BASMI (0–10) 3.45 (2.63) 2.76 (2.5) 3.74 (2.64) 5.31 (2.12) 0.0010
Duration of morning stiffness (minutes) 51.03 (40.3) 45.55 (36.13) 56.43 (48.2) 57.5 (35.82) 0.4528
Evaluation of enthesitis (0–10) 3.73 (3.21) 3.07 (3.02) 4.46 (3.08) 4.5 (3.83) 0.0692
Pain in spine (0–10) 5.39 (2.94) 4.65 (2.68) 5.8 (3.21) 6.81 (2.51) 0.0119
Global well-being (0–10) 4.88 (2.28) 4.42 (2.36) 5.14 (2.09) 5.88 (2.16) 0.0561
Fatigue (0–10) 4.96 (2.64) 4.18 (2.52) 5.23 (2.79) 6.88 (1.36) 0.0007
pa value according to Kruskal-Wallis test
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of spine pain and fatigue in comparison with the groups
with overweightness and obesity. The differences between
the groups in peripheral arthritis (p = 0.769) and uveitis (p =
0.614) during the course of the disease, age of AS onset (p
= 0.3269), duration of morning stiffness (p = 0.4528), ex-
pression of enthesitis (p = 0.0692) and global wellbeing (p
= 0.0561) were not statistically significant.
The data clearly showed that patients who were overweight
or obese had higher disease activity (ASDAScrp (p =
0.0060), BASDAI (p = 0.0088)) with more expressed func-
tional and spinal mobility impairment evaluated accordingly
as BASFI (p = 0.0002) and BASMI (p = 0.0010). Thus,
BMI can be used as an objective indirect evaluation of the
severity of systemic inflammation and/or the consequence
of it expressed by functional disability and spinal mobility
impairment. Reversible spinal inflammation causes irrevers-
ible structural damage leading to spinal mobility impair-
ment and functional disability (Sieper et al., 2008). Interest-
ingly, data obtained from the Korean College of
Rheumatology BIOlogics registry revealed that increased
BMI is significantly associated with the presence of
syndesmophyte, but not with disease activity in axial
spondyloarthritis (SpA) (Kim et al., 2017). Based on data
from the SPACE cohort on possible impact of BMI to the
ASDAS in axial SpA — ASDAS is not affected by BMI in
axial SpA patients. The results from SPACE cohort showed
that correlations between BMI and CRP or patient-reported
outcomes (included in ASDAS) were generally weak
(Vargas et al., 2016). In contrast, other authors concluded
that BMI is associated with the level of disease activity and
functional ability (Durcan et al., 2012; Maas et al., 2016).
Additionally, based on data (Durcan et al., 2012) from a co-
hort of 46 AS patients, 67.5% were overweight or obese —
they had a greater burden of symptoms, worse perceptions
regarding the benefits of exercise, and enhanced awareness
of their barriers to exercising, which raised particular con-
cern for the disease as exercise plays a crucial role. Thus,
the recommendation for AS patients to decrease the BMI to
the appropriate level is relevant for achievement of remis-
sion.
One of the most frequently reported symptoms by patients
with axial SpA is disease-related fatigue (Dernis-Labous et
al., 2003). It is a significant component of chronic inflam-
matory disease defined as dysfunctional, long-lasting and
persisting condition, despite adequate periods of rest and
sleep (Davies et al., 2013). In our study, fatigue was evalu-
ated by using NRS thus showing the intensity without a de-
scription of the duration, time of expression during the day,
nor differentiation of physical and psychological input in
the evaluation of fatigue. The mean evaluation of fatigue in
our patients was high enough, with higher evaluation in the
group with obesity (p = 0.0007), thus emphasizing the im-
pact of extraspinal manifestations to the course of the dis-
ease. In contrast, not all studies showed a link between fa-
tigue and BMI. For example, in a previous study (Alkan et
al., 2015) on the Multidimensional Assessment of Fa-
tigue (MAF) for patients with AS, a correlation with BMI
was not observed. There was a statistically significant dif-
ference between the groups on back pain evaluation (p =
0.0119) — patients with overweight and obesity had higher
scores for back pain level. Thus, an approach to reduce the
negative impact of the disease and on the quality of life
should be focused on, as well as to reduce the high BMI.
Our data on peripheral arthritis and uveitis is consistent
with the published data of meta-analysis on extraspinal
manifestations in AS (de Winter et al., 2016): 18–58%
prevalence of arthritis and 22–37% of uveitis (all reported at
any time during the disease). To our knowledge this is the
first study ever reported that analysed the link between BMI
and uveitis or peripheral arthritis in the course of AS. The
impact of the presence of uveitis during the course of AS
still remains a challenge. There is data showing that a his-
tory of iritis is independently associated with a worse radio-
logical outcome in AS (Doran et al., 2003). Previous results
(Heuft-Dorenbosch et al., 2004) showed that AS patients
with peripheral arthritis had higher BASDAI than AS pa-
tients without extraspinal articular manifestation. This can
be explained by two factors: higher evaluation of the
BASDAI question on peripheral pain as well as higher val-
ues answering other questions regarding fatigue, morning
stiffness, spinal pain, and enthesopathy. Thus, peripheral
manisfestations contribute to higher disease activity, possi-
bly due to a more extensive inflammation. Interestingly,
data from the observation study of the Korean Spondyloar-
thropathy Registry concluded that the presence of peripheral
arthritis delays spinal radiographic progression in AS (Kim
et al., 2014). Thus, the clinical and radiological impact of
peripheral arthritis as well as the link between inflammation
and structural damage in patients with axial SpA, particu-
larly AS, still remains a challenge. Our study showed no re-
liable impact of the history of uveitis and peripheral arthritis
on BMI expression (accordingly, p = 0.614 and p = 0.769).
Therefore, it can be considered that extraspinal manifesta-
tions such as uveitis and peripheral arthritis are more con-
nected with other cytokine pathways than overweight/obe-
sity.
CONCLUSION
AS patients who were overweight and obese had a higher
level of disease activity, pain level, fatigue score, functional
disability and spinal mobility impairment with higher val-
ues in the case of obesity. The results of this study suggest
that the BMI can be used as one of the indirect objective
clinical signs, which shows the expression of systemic in-
flammation and induced impairment of mobility in the
course of the disease independent on the age of AS onset
and predict the response to the treatment.
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ÍERMEÒA MASAS INDEKSA IETEKME ANKILOZÇJOÐÂ SPONDILÎTA PROGRESIJÂ
Aptaukoðanâs ir viens no faktoriem, kas var ietekmçt hroniska, sistçmiska iekaisuma artrîta gaitu. Mûsu pçtîjuma mçríis bija raksturot
pacientus ar ankilozçjoðo spondilîtu (AS) atkarîbâ no íermeòa masas indeksa (ÍMI), izpçtot saistîbu starp virssvaru un aptaukoðanos un
ikdienâ izmantojamiem slimîbas novçrtçjuma instrumentiem, ieskaitot slimîbas aktivitâtes (BASDAI, ASDAScrp), mugurkaula kustîguma
(BASMI), funkcionâlo spçju (BASFI) novçrtçjuma indeksus, ârpusmuguras izpausmçm kâ nespçks, uveîts, perifçrs artrîts (jebkad slimîbas
laikâ). Ðíçrsgriezuma pçtîjumâ tika iekïauti 107 pacienti atbilstoði modificçtiem Òujorkas AS kritçrijiem. Pacienti tika iedalîti trijâs grupâs
atkarîbâ no ÍMI:  24,9, 25,0–29,0 un  30,0 kg/m2. Vidçjâ ÍMI vçrtîba bija 25,13 (SD 4,07). 33% pacientu bija ar virssvaru un 15% ar
aptaukoðanos. Vecuma, slimîbas ilguma, ASDAScrp, BASDAI, BASFI, BASMI, nespçka novçrtçjuma vidçjâs vçrtîbas pacientiem ar normâlu
ÍMI bija zemâkas, salîdzinot ar pârçjâm grupâm (p < 0,05). Statistiski ticamas atðíirîbas starp grupâm netika konstatçtas, izvçrtçjot
slimîbas pirmo simptomu parâdîðanâs vecumu, perifçro artrîtu un uveîtu (noteiktu jebkad slimîbas laikâ). Saskaòâ ar mums pieejamâs
zinâtniskâs literatûras datiem mûsu pçtîjumâ pirmo reizi esam izvçrtçjuði ÍMI saistîbu ar uveîta un perifçra artrîta sastopamîbu AS slimîbas
gaitâ. AS pacientiem ar virssvaru vai aptaukoðanos ir augstâka slimîbas aktivitâte, sâpju un nespçka novçrtçjums, funkcionâlâs nespçjas
indekss un mugurkaula kustîguma traucçjumu pakâpe, turklât augstâki rezultâti ir grupâ pacientiem ar aptaukoðanos.
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